Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Akeso Management

Management Kriterienprüfungen 3/4

Akeso's CEO ist Michelle Xia, ernannt in Mar 2012, hat eine Amtszeit von 12.17 Jahren. Die jährliche Gesamtvergütung beträgt CN¥6.52M, bestehend aus 67% Gehalt und 33% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 9.1% der Aktien des Unternehmens, im Wert von HK$2.92B. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.8 Jahre bzw. 4.5 Jahre.

Wichtige Informationen

Michelle Xia

Geschäftsführender

CN¥6.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	67.0%
Amtszeit als Geschäftsführer	12.2yrs
Eigentum des Geschäftsführers	9.1%
Durchschnittliche Amtszeit des Managements	3.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.5yrs

Jüngste Management Updates

Recent updates

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Apr 24

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Mar 25

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Dec 28

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Nov 16

Is Akeso (HKG:9926) Using Too Much Debt?

Oct 02

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Mar 21

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Mar 02

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Aug 28

Is Akeso (HKG:9926) Using Too Much Debt?

Apr 10

Akeso (HKG:9926) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Dec 28

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Michelle Xia im Vergleich zu den Einnahmen von Akeso verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	CN¥7m	CN¥4m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥409m
Dec 31 2022	CN¥5m	CN¥4m	-CN¥1b
Sep 30 2022	n/a	n/a	-CN¥1b
Jun 30 2022	n/a	n/a	-CN¥1b
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥7m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥929m
Mar 31 2021	n/a	n/a	-CN¥983m
Dec 31 2020	CN¥7m	CN¥3m	-CN¥1b
Sep 30 2020	n/a	n/a	-CN¥870m
Jun 30 2020	n/a	n/a	-CN¥703m
Mar 31 2020	n/a	n/a	-CN¥492m
Dec 31 2019	CN¥2m	CN¥1m	-CN¥282m

Vergütung im Vergleich zum Markt: MichelleDie Gesamtvergütung ($USD900.76K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD472.14K).

Entschädigung vs. Einkommen: MichelleDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Michelle Xia (56 yo)

12.2yrs

Amtszeit

CN¥6,524,000

Vergütung

Dr. Yu Xia, Ph D., also known as Michelle, is CEO & President of Akeso Biopharma, Inc. Dr. Xia is Founder of Akeso, Inc. Dr. Xia is CEO, President & Chairwoman of Akeso, Inc. from March 19, 2012. She has b...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yu Xia	Founder	12.2yrs	CN¥6.52m	9.1% CN¥ 2.9b
Baiyong Li	Co-Founder	12.2yrs	CN¥5.02m	6.2% CN¥ 2.0b
Zhongmin Wang	Co-Founder	no data	CN¥3.60m	5.22% CN¥ 1.7b
Yu Xia	Senior VP & Executive Director	4.5yrs	CN¥33.65m	keine Daten
Peng Zhang	Co-Founder & Senior VP	no data	keine Daten	keine Daten
Xinfeng Zhang	Senior Vice President	3.8yrs	keine Daten	keine Daten
Wenjun Shi	Senior Vice President	3.8yrs	keine Daten	keine Daten
Mingxiu Hu	Senior Vice President	2.3yrs	keine Daten	keine Daten
Charlie Zhang	Senior Vice President	1.3yrs	keine Daten	keine Daten
Jing Min	Senior Vice President	1.3yrs	keine Daten	keine Daten
Wai Yan Leung	Company Secretary	1.8yrs	keine Daten	keine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: 9926Das Führungsteam des Unternehmens gilt als erfahren (3.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yu Xia	Founder	12.2yrs	CN¥6.52m	9.1% CN¥ 2.9b
Baiyong Li	Co-Founder	4.5yrs	CN¥5.02m	6.2% CN¥ 2.0b
Zhongmin Wang	Co-Founder	4.5yrs	CN¥3.60m	5.22% CN¥ 1.7b
Yu Xia	Senior VP & Executive Director	4.5yrs	CN¥33.65m	keine Daten
Bo Tan	Independent Non-Executive Director	no data	CN¥317.00k	keine Daten
Ronggang Xie	Non-Executive Director	3.8yrs	keine Daten	keine Daten
Yi Zhou	Non-Executive Director	4.5yrs	keine Daten	keine Daten
Yan Xu	Independent Non-Executive Director	no data	CN¥319.00k	keine Daten
Junwen Zeng	Independent Non-Executive Director	no data	CN¥317.00k	keine Daten

4.5yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrener Vorstand: 9926Die Vorstandsmitglieder gelten als erfahren (4.5 Jahre durchschnittliche Amtszeit).

Akeso Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Founder recently sold HK$96m worth of stock

Co-Founder recently sold HK$4.4m worth of stock

Akeso, Inc., Annual General Meeting, Jun 28, 2023

Less than half of directors are independent

Akeso, Inc., Annual General Meeting, Jun 28, 2022

Less than half of directors are independent

Recent updates

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Is Akeso (HKG:9926) Using Too Much Debt?

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2023

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Now 24% undervalued

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile

Forecast to breakeven in 2023

Less than half of directors are independent

Akeso, Inc. Announces Ivonescimab Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

No longer forecast to breakeven

Akeso's Ivonescimab (PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC

Akeso, Inc. Develops Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors

Akeso, Inc. Announces Commencement of Phase Ib/II clinical trial

Forecast to breakeven in 2024

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Akeso, Inc. Publishes First Approval of Cadonilimab in Drugs, A Peer-Reviewed Medical Journal

Akeso, Inc. to Report First Half, 2022 Results on Aug 23, 2022

Akeso's Cadonilimab (Pd-1/Ctla-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China